Pancreatic Cancer Research

ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Jiahong Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0500-2278; OpenAlex author ID A5066202474. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]. Co-author DOI 10.1016/j.gendis.2024.101352↗
  2. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. Co-author DOI 10.1016/j.gendis.2022.02.014↗
  3. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Co-author DOI 10.3389/fimmu.2021.691605↗
  4. Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.771247↗
  5. A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment Co-author DOI 10.21203/rs.3.rs-130888/v1↗
  6. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01220↗
  7. Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review. Co-author DOI 10.3389/fphar.2020.579239↗
  8. Immunotherapy in pancreatic cancer: New hope or mission impossible? Co-author DOI 10.1016/j.canlet.2018.10.045↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liu Yang · 5 shared papers, 2019–2023 · strength 0.66
  2. Dongsheng Huang · 4 shared papers, 2019–2021 · strength 0.46
  3. Zheling Chen · 4 shared papers, 2020–2021 · strength 0.45
  4. Wan‐Xin Peng · 2 shared papers, 2023–2024 · strength 0.45
  5. Yin‐Yuan Mo · 2 shared papers, 2023–2024 · strength 0.45
  6. Yunyun Xu · 3 shared papers, 2020–2021 · strength 0.32
  7. Yang Liu · 1 shared paper, 2024 · strength 0.24
  8. Xiaoge Hu · 2 shared papers, 2019–2020 · strength 0.22
  9. Mingxing Wang · 1 shared paper, 2020 · strength 0.11
  10. Yiping Mou · 1 shared paper, 2019 · strength 0.11
  11. Liang Liu · 1 shared paper, 2020 · strength 0.09
  12. Liu Yang · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.